Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis View HTML
Toggle Summary Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease View HTML
Toggle Summary Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid View HTML
Toggle Summary Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL
Company Also Presents Data on Novel Dual FXR/TGR5 Agonist INT-767
View HTML
Toggle Summary Intercept Pharmaceuticals Raises $25 Million Series B Financing
Dr. Lorenzo Tallarigo Appointed Chairman
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment of Primary Biliary Cirrhosis View HTML
Toggle Summary Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
Company to Present Data at EASD Plenary Session
View HTML
Toggle Summary Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity View HTML
Toggle Summary Nature Publication Reports on Key Roleof Bile Acids in Glucose Metabolism and Insulin Signaling View HTML
Toggle Summary Intercept Pharmaceuticals Raises $25 Million
Funding Will Support Completion of INT-747 Phase II Clinical Trials and Acceleration of Pipeline Development
View HTML